Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: Four case reports and a review of drug-induced psoriasis - 11/09/11
From the Divisions of Dermatologya and Clinical Pharmacology,c the Department of Medicine, Sunnybrook Health Science Center, the Womens' College Hospital,b Toronto Western Hospital,d and the University of Toronto.
Abstract |
Adverse effects may occur in 10.4% of patients receiving terbinafine therapy, with cutaneous reactions in 2.7%. We describe the development of psoriasis in four patients who took oral terbinafine. Two patients had plaque-type psoriasis that flared 12 and 17 days, respectively, after starting terbinafine. Another patient developed pustular-type psoriasis de novo after 27 days of terbinafine therapy. The fourth patient was a psoriatic with stable plaque disease who experienced a pustular flare after taking terbinafine for 21 days. We are aware of only one report in the literature in which a patient developed pustular psoriasis de novo after 5 days of terbinafine therapy. In all patients the psoriasis cleared or lessened after discontinuation of terbinafine and institution of antipsoriatic therapy. (J Am Acad Dermatol 1997;36:858-62.)
Le texte complet de cet article est disponible en PDF.Plan
This article is made possible through an educational grant from the Dermatological Division, Ortho Pharmaceutical Corporation. |
|
Reprints not available from the authors. |
|
0190-9622/97/$5.00 + 0 16/4/77693 |
Vol 36 - N° 5S
P. 858-862 - mai 1997 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?